Related by context. All words. (Click for frequent words.) 73 pyrexia mucositis sepsis febrile 73 receiving XGEVA 72 prednisone prednisolone plus 71 plus glimepiride 71 oxycodone CR 71 abdominal pain abdominal discomfort 70 neutropenia dehydration dyspnea 70 8mg/kg 70 ACTEMRA TM 69 headache abdominal pain 69 headache nasopharyngitis 69 somnolence dizziness 69 TAXUS p value 69 morphometric vertebral fractures 68 REYATAZ r arm 68 receiving VELCADE 68 4mg/kg 68 dizziness nausea diarrhea 68 lopinavir r arm 68 PREZISTA r arm 68 receiving INTRON 68 mcg BID 68 infliximab monotherapy 68 incidence ≥ 68 nasopharyngitis headache 68 plus OBT 67 -#.# log# copies mL 67 achieved ACR# 67 receiving golimumab 67 dapagliflozin plus 67 mg p = 67 PLX STROKE targeting 67 included exfoliative dermatitis 67 diarrhea nausea fatigue 67 certolizumab 67 mcg linaclotide 66 angioneurotic edema 66 superficial edema 66 mcg kg REBETOL 66 rimonabant #mg/day 66 dizziness somnolence 66 moderate renal impairment 66 mg BID dose 66 TEAEs 66 insomnia somnolence 66 Erythropoietic therapies may 66 discontinuations due 66 mg metformin 66 Infusion Reactions Severe 66 severe exacerbations 66 neutropenia thrombocytopenia 66 myocardial infarction ventricular fibrillation 66 receiving CIMZIA #mg 66 naïve HCV 66 nausea dizziness vomiting 66 didanosine associated 66 mild renal insufficiency 66 HBeAg negative patients 65 MADRS score 65 -#.# mg dL [002] 65 fatigue asthenia 65 receiving FUSILEV 65 oxycodone IR 65 budesonide pMDI 65 REMICADE monotherapy 65 Discontinuations due 65 rectal tenesmus 65 del 5q MDS 65 anaphylactic reactions bronchospasm 65 generalized edema 65 placebo p = 65 relapsed MM 65 adjunctive ABILIFY 65 laboratory abnormalities 65 receiving TNF blockers 65 STELARA ® 65 treatment emergent adverse 65 plus prednisone prednisolone 65 ARCALYST ® 65 baseline HbA1c 65 tapentadol ER 65 peripheral sensory neuropathy 65 quetiapine XR 65 tapentadol IR 65 serum phosphorous 65 receiving PEGINTRON 65 #mg BID [001] 64 plus aztreonam 64 Budesonide foam crofelemer 64 events TEAEs 64 plus methotrexate 64 nasopharyngitis 64 #mg BID [003] 64 Hazard Ratio HR 64 pruritus rash 64 unresectable HCC 64 Zometa hazard 64 fluticasone salmeterol 64 Rate ORR 64 placebo p 64 myalgia arthralgia 64 chills fever headache 64 #mg/day [001] 64 nasopharyngitis upper 64 mcg QD 64 FluCAM arm 64 ACR# ACR# 64 desvenlafaxine succinate 64 elevated ALT 64 highly emetogenic 64 TLUS 64 % #gt 64 Non inferiority 64 plus dexamethasone 64 headache tiredness dizziness 64 -#.# mg dL [001] 64 hematologic adverse 64 arterial thromboembolic events 64 SSRI SNRI 64 Febrile neutropenia 63 adverse reactions incidence 63 diarrhea flatulence 63 PASI scores 63 tolterodine ER 63 Mg Uk 63 mg TID 63 deep venous thromboses 63 sUA 63 diarrhea dyspepsia 63 ug dose 63 VIIBRYD 63 lumbar spine BMD 63 ADCS CGIC 63 severe hepatic dysfunction 63 mitoxantrone plus 63 Exacerbations 63 statistically significant p = 63 Clostridium Difficile Associated 63 #.#/#.# mmHg [001] 63 echinacea tablets 63 symptomatic hyponatremia 63 diarrhea headache nausea 63 nausea diarrhea fatigue 63 haematologic 63 ocular adverse 63 Score TOS 63 Castration Resistant Prostate Cancer 63 R adefovir dipivoxil 63 events thrombocytopenia neutropenia 63 #mg/day [002] 63 neutropenic sepsis 63 0 document.write 63 Relapsed Multiple Myeloma 63 tipranavir r 63 HBeAg + 63 CYP#A# substrate 63 aspirin clopidogrel 63 RLAI 63 difficile associated 63 salmeterol fluticasone 63 NNT = 63 Mg Usa 63 BENICAR HCT 63 infections gastrointestinal perforations 63 titrated glipizide plus 63 leucopenia 63 somatostatin analog 62 statistically significant p 62 Zemplar Capsules 62 oral hypoglycemic agent 62 Infusion reactions 62 High Dose quadruples 62 pharyngolaryngeal pain 62 Relapsing Multiple Sclerosis 62 headache arthralgia 62 hyperphenylalaninemia HPA due 62 Bronchopulmonary Dysplasia 62 diarrhea nausea abdominal pain 62 headache nausea diarrhea 62 decompensated liver disease 62 opioid naive 62 diarrhea nausea vomiting 62 adjunctive placebo 62 mg Proellex 62 fatigue nausea vomiting 62 Oral Fingolimod 62 fatigue abdominal pain 62 3mg/kg 62 mg ustekinumab 62 adverse reactions ≥ 62 oral FTY# 62 undergoing elective percutaneous 62 using lactulose concomitantly 62 nausea somnolence 62 Brief Psychiatric 62 x ULN 62 ecchymosis 62 GOUT 62 nonhematologic adverse reactions 62 YOUR LOCAL ANIMAL SHELTER 62 rectal tenesmus #.# 62 transaminase elevations 62 Montgomery Asberg Depression 62 Xalatan R 62 #:#-#,# CrossRef Medline [001] 62 CYT# potent vascular disrupting 62 nonsignificant difference 62 oral prednisolone 62 R# #mg BID 62 Biaxin R 62 See CLINICAL PHARMACOLOGY 62 APTIVUS r 62 See WARNINGS 62 nausea respiratory distress 62 thrombocytopenia anemia 62 achieved statistical significance 62 statistical significance p 62 BARACLUDE ® 62 mild renal impairment 62 EFFEXOR XR 62 Services #:#-#,# Abstract 62 HIV HCV coinfected 62 humanized interleukin 6 62 Severe hypersensitivity reactions 62 nausea vomiting cramps 62 Lupuzor ™ 62 0 document.write sline 62 recurrent venous thromboembolism 62 liver transaminases 62 prolonged QT interval 62 % #lt ;/ 62 Perforomist Inhalation Solution 62 asthenia fatigue 62 systemic invasive fungal 62 recurrent glioblastoma multiforme 62 Raptiva r 62 formoterol DPI 62 HIV coinfected 62 VANTAS ® 62 Relapsing Remitting Multiple Sclerosis 62 NATRECOR R 62 oral antidiabetic medication 62 FUSILEV enhances 62 events AEs 62 affective psychosis 62 TOVIAZ 62 dermatologic reactions 62 convulsive disorders 62 microbiological eradication 62 anemia constipation diarrhea 62 INVEGA ® 62 reactogenicity 61 Hamilton Anxiety Scale 61 events SAEs 61 ARCOXIA 61 inflammatory PDE 61 hematological adverse 61 bone marrow reticulin deposition 61 administered cetrorelix 61 biologic DMARD 61 SHOWS TO WATCH 61 achieved CCyR 61 demonstrated clinically meaningful 61 Treatment emergent adverse 61 DETROL LA 61 Malignant Glioma 61 constipation dizziness 61 malignancy HCM 61 TYSABRI treated 61 adverse reactions occurring 61 anemia leukopenia 61 CI -#.# 61 prospectively stratified 61 evaluating tivozanib 61 concomitant cardiac 61 colesevelam HCl 61 Flu Cy 61 investigational saxagliptin 61 reduce serum phosphate 61 solifenacin 61 adefovir treated 61 Secondary endpoints included 61 induce orthostatic hypotension 61 Chemotherapy induced 61 PEGINTRON TM 61 weekly CSBMs 61 EXJADE 61 oral rivaroxaban 61 mcg albinterferon alfa 2b 61 ATACAND 61 treatment emergent AEs 61 myopathy rhabdomyolysis 61 NPH insulin 61 unfractionated heparin UFH 61 EURIDIS 61 CIMZIA TM certolizumab pegol 61 Engerix B 61 abdominal pain flatulence 61 CTAP# 61 HBeAg seroconversion 61 KAPVAY 61 non splenectomized 61 Renal Impairment 61 brand ciclesonide HFA 61 Study Shows Promise 61 stage IIIb IV 61 titrated glipizide 61 PEGINTRON REBETOL combination 61 severe NCI CTC 61 proctitis 61 constipation nausea 61 urinary N telopeptide 61 Ceplene/IL-2 61 dyslipidemia hypertension diabetes 61 febrile neutropenia 61 mg qd 61 venlafaxine XR 61 baseline FEV 61 Bipolar Mania 61 NSAID associated 61 mmHg p = 61 mg XP# 61 BMS p = 61 advanced hepatocellular carcinoma 61 constipation OIC 61 stiffness nausea abdominal pain 61 ACR# response 61 neutropaenia 61 #.#mg/dL 61 Hematologic toxicity 61 Pharmacokinetic parameters 61 receiving VICTRELIS 61 receiving ISENTRESS 61 ALT flares 61 GERD symptom 61 IOP lowering 61 Hill Rom enhancing 61 symptomatic VTE 61 EDARBI 61 vaginal progesterone gel 61 neutropenia febrile neutropenia 61 -#.# log# 61 liver enzymes ALT 61 azilsartan medoxomil 61 Crofelemer budesonide foam 61 fever headaches nausea 61 ABILIFY Injection 61 Telithromycin 61 Ribavirin causes 61 J Foot Ankle 61 fluoxetine paroxetine 61 treatment naive genotype 61 Adjunctive Therapy 61 Secondary endpoints include 61 -#.# mm Hg 60 serologically active systemic lupus 60 CYP#A# CYP#D# 60 comparator arm 60 mg kg belimumab 60 microbiologically evaluable 60 Index CDAI 60 tirofiban 60 HbA1C levels 60 zolmitriptan 60 Oropharyngeal Candidiasis 60 Negative Symptoms 60 & s2 = 60 cramping abdominal pain 60 oral levofloxacin 60 antiretroviral naïve 60 Herpes infections 60 included neutropenia anemia 60 ACR# responses 60 cisplatin gemcitabine 60 Warfarin Coumadin 60 chronic diarrhea abdominal 60 CIMZIA TM 60 TMC# r 60 nadroparin 60 FDA Approves Novel 60 VELCADE melphalan 60 glipizide plus 60 FDA defined valvulopathy 60 LAMICTAL 60 R entecavir 60 placebo dexamethasone 60 moderate hepatic impairment 60 patients receiving ERBITUX 60 RECORD1 60 FOLFIRI alone 60 Dementia Related Psychosis 60 Nausea vomiting 60 Timed Walk 60 Known hypersensitivity 60 confidence interval #.#-#.# 60 bortezomib refractory 60 plus COPEGUS 60 Desvenlafaxine Succinate 60 administering XIFAXAN 60 headache diarrhea nausea 60 mg kg Hematide 60 benazepril 60 splenectomized 60 extrapyramidal symptoms 60 receiving highly emetogenic 60 MCyR 60 % Confidence Interval 60 Patients Receiving 60 leukopenia 60 thrombosis embolism 60 thrombocytopenia neutropenia 60 CI #.#-#.# [002] 60 Primary endpoints 60 J Shoulder Elbow 60 albiglutide 60 headache somnolence 60 ord = + krdDartOrd 60 elevated transaminases 60 asthenia weakness 60 TWYNSTA 60 LEXIVA r 60 Ophena TM 60 Acneform rash occurred 60 pooled comparator 60 mg dosed twice 60 neuropathy sensory 60 CIMZIA ™ 60 mcg mL 60 ZOMIG Nasal Spray 60 Xeloda ® 60 QTcF 60 known dihydropyrimidine dehydrogenase 60 SYMBICORT pMDI 60 vitreous floaters 60 lopinavir r 60 Neutropenia 60 serum leptin 60 EMBLEM TM 60 aldosterone antagonists 60 daily Infergen 60 myelodysplastic myeloproliferative diseases 60 pruritus itching 60 Refractory Hodgkin Lymphoma 60 DOXIL 60 inhalations twice 60 HUMIRA achieved PASI 60 myalgia muscle 60 DO NOT THINK HE 60 ALT elevation 60 Meets Primary Endpoint 60 Myelosuppression 60 rosuvastatin #mg 60 IIIa inhibitor 60 infection epistaxis dyspnea exfoliative 60 MULLIGAN FAMILY FUN CENTER 60 BARACLUDE r 60 BPH Symptom Score 60 IXEMPRA 60 doxorubicin cyclophosphamide 60 DAS# scores 60 serratia sepsis may 60 â ‰ ¥ 60 placebo fluoxetine 60 ACEIs 60 Illnesses ranged 60 rimonabant #mg 60 PREZISTA r 60 scores TNSS 60 FluCAM 60 alfuzosin 60 intravenous RSD# 60 unstable angina pectoris 60 experienced hypomagnesemia 60 XIENCE V vs. 60 bepotastine besilate nasal spray 60 microgram kg 60 mg + GLY 60 refractory NSCLC 60 CANCIDAS 60 dose pravastatin 60 heFH 60 comorbid ADHD 60 mg BID 60 Discontinuations 60 R Bortezomib 60 CHANGE WEEKLY CHANGE 60 Fasting blood glucose 60 elevated lipase 60 hypophosphatemia 60 Stent thrombosis 60 #mg BID [002] 60 hormone receptor negative 60 acneform rash 60 TSY YLD 60 nicardipine 60 Treatment Shows Promise 60 Hepatitis C Antiviral 60 DAS# remission 60 chronically immunosuppressed solid 59 By JENNIFER LEARN 59 CAPRIE 59 PREZISTA ritonavir 59 full var buttonHeight 59 beclomethasone dipropionate 59 chills fatigue 59 MACUGEN 59 #-#-# drlg [001] 59 cough dyspnea 59 zoledronic acid Reclast 59 novel orally inhaled 59 Aeolus Pharmaceuticals Announces 59 catheter occlusion 59 Adenoviruses usually cause 59 nausea vomiting headache 59 FOLPI 59 #mg #mg #mg [003] 59 dermatologic toxicities 59 fatal anaphylactic 59 www.BYETTA.com 59 demonstrated antitumor activity 59 oral ribavirin 59 headache nausea fatigue 59 Community Acquired Pneumonia 59 Premature Infants 59 adverse reactions irrespective 59 somnolence fatigue 59 Improves Outcomes 59 p ≤ 59 metastatic colorectal carcinoma 59 ischemia driven 59 suboptimal adherence 59 spontaneous bowel movements 59 mineralized uncut 59 non squamous histology 59 dizziness imbalance 59 Suicidal tendencies 59 ‰ ¥ 59 CINQUIL 59 abdominal pain headache 59 anemia hemoglobin 59 adriamycin 59 seroprotection 59 paresthesias 59 baseline A1C 59 β blocker 59 Heterozygous Familial Hypercholesterolemia 59 venlafaxine Effexor 59 Renal impairment 59 LEVAQUIN ® 59 MDS MPD 59 nausea vomiting stomach cramps 59 paliperidone ER 59 metabolic alkalosis 59 mild hepatic impairment 59 eosinophilic asthma 59 baseline serum creatinine 59 Inhaled Nitric Oxide 59 Cytarabine Liposome Injection 59 recurrent ischemia 59 Danazol 59 gastrointestinal adverse reactions 59 HBeAg positive patients 59 paroxetine sertraline 59 recurrent DVT 59 oral talactoferrin 59 nadolol 59 echocardiographic parameters 59 Adefovir 59 vascular occlusive diseases 59 baseline PASI 59 severe hypersensitivity reactions 59 primidone 59 abacavir lamivudine 59 atorvastatin #mg 59 peripheral edema 59 patients coinfected 59 nausea constipation 59 methotrexate monotherapy 59 avosentan 59 NUCYNTA ™ 59 hematologic toxicity 59 basal bolus therapy 59 alfa 2a 59 Dyspepsia Tachycardia Myalgia etc. 59 Lactic acidosis 59 rhinitis sinusitis 59 Lipitor #mg 59 SGPT 59 inhaled budesonide 59 CIMZIA R 59 Prolongs Survival 59 Primary Endpoint 59 MARKET TALK Saudi 59 post herpetic 59 PCT VALUE DATE 59 nondiabetic patients 59 racemic albuterol 59 Jingle spina bifida 59 Severity MSCS score 59 salmeterol fluticasone propionate 59 Reduces Mortality 59 serum urate 59 XIENCE V demonstrated 59 Primary Hypercholesterolemia 59 Generalized Anxiety Disorder 59 abdominal pain diarrhea nausea 59 5-FU/LV 59 fever nausea abdominal 59 neutropenia anemia 59 hematological parameters 59 RAPTIVA 59 Randomized Double Blind 59 CTAP# Capsules 59 ARIXTRA 59 lipid lowering agents 59 LymphoStat B belimumab 59 Carotid Artery Disease 59 Effexor venlafaxine 59 topical gel formulation 59 atherosclerosis rheumatoid arthritis 59 pegylated interferon alfa 2b 59 Peripheral edema 59 limiting toxicity DLT 59 Hypomagnesemia occurred 59 HBsAg positive 59 annualized relapse 59 Severe cutaneous 59 treatment naïve genotype 59 mg QD 59 ARB telmisartan 59 Hypocalcemia 59 receiving chemoradiation therapy 59 ACE Inhibitors 59 Rating Scale MADRS 59 inhaled glucocorticoids 59 hypomagnesemia 59 tolvaptan 59 Angiograms carry slight 59 CompX Reports 59 #:#-#,# CrossRef Medline [002] 59 airway obstruction bronchospasm stridor 59 R Saizen R 59 WEEK ENDING INDEX 59 TMP SMX 59 Treatment Naive Patients 59 MAGE A3 ASCI 59 mcg doses 59 BUPHENYL 59 binary restenosis 59 Folfox 59 MACCE 59 severe hypoglycemic 59 Apolipoprotein B 59 intracranial atherosclerosis 59 % CI #.#-#.# [003] 59 HAM D# scores 59 rituximab refractory 59 saline placebo 59 AND P.codeprof = AE.codeprof 59 Hypertensive adverse reactions 59 intravascular hemolysis 59 angina myocardial infarction 59 BEXXAR Therapeutic Regimen 59 moderate hepatic insufficiency 59 Genes Predict 59 Is Well Tolerated 59 anorexia nausea vomiting 59 mg Androxal 59 colorectal adenoma 59 oral olanzapine 59 diabetic peripheral neuropathic DPN 59 muscles abdominal distension 59 CYP#A# isoenzyme 59 tuberculosis TB sepsis 59 hives itching 59 thromboembolic complications 59 #-#,# mg 59 hematological toxicity 59 abdominal cramping vomiting 59 transaminase elevation 59 % CI #.#-#.# [007] 59 RBD Palmolein FOB 59 Vertebral fractures 59 genitourinary GU 59 dyspnea dermatitis eczema 59 overt hepatic encephalopathy HE 59 venlafaxine ER 59 definite stent thrombosis 59 Shows Promise Against 59 T1c 59 Sleep Disturbances 59 Thal Dex 59 % CI #.#-#.# [005] 59 Zeldox 58 hypertension pulmonary arterial 58 Psoriasis Area 58 diarrhea vomiting nausea 58 plus GP IIb 58 candesartan cilexetil 58 umol L 58 Elderly Patients 58 ULORIC 58 Research www. elsevier.com 58 Hydrochlorothiazide Tablets 58 plus MTX 58 Ishak fibrosis score 58 acute febrile 58 nephropathic cystinosis cystinosis 58 Arterial stiffness 58 BY DAVID CRIGGER 58 rizatriptan 58 opioid naïve 58 GLIADEL R Wafer 58 Peginterferon 58 Fibromyalgia Impact Questionnaire 58 achieved PASI 58 kilometers FTK 58 CONTRIBUTE TO THE 58 nitroprusside 58 NATRECOR ® 58 Operative mortality 58 causality incidence 58 By Dave Ornauer 58 corticosteroid dose 58 aspirin heparin 58 tamoxifen Nolvadex ® 58 minimally symptomatic 58 Teriflunomide 58 Hepatotoxicity 58 Shows Efficacy 58 Treatment discontinuations due 58 Hypersensitivity reactions 58 BILLION DOLLARS IN 58 antiplatelet medications 58 Apidra ® 58 Greg Stanfield GXP 58 complement inhibitor eculizumab 58 mg simvastatin 58 boys Khoran Brown 58 Diarrhea vomiting 58 STRIDE PD 58 Post Menopausal 58 venous thromboembolic disease 58 serum aminotransferase levels 58 Tumor Response 58 oral allopurinol 58 glulisine 58 PROVES THAT 58 known sulfonamide allergy 58 % 3C/script 58 Vildagliptin 58 rheumatoid arthritis inflammatory bowel 58 Luvox fluvoxamine 58 d l leucovorin 58 Demonstrated Significant 58 mCi kg 58 spud #-#-# drlg [001] 58 Therapy Improves 58 #rd Annual CTRC 58 Gene Mutation Linked 58 IBS C 58 FFNS 58 NorStates Bank serves 58 achieved sustained virologic 58 KRAS mutations occur 58 metformin monotherapy 58 DAS# CRP 58 follicular lymphomas 58 Tipranavir 58 develop HBV reactivation 58 THOUSAND DOLLARS IN 58 μg dose 58 ritonavir boosted 58 arthralgia 58 OAB symptoms 58 Peginterferon Alfa 2a 58 commonly thrombocytopenia 58 FOLFOX regimen 58 tipranavir ritonavir 58 extrapyramidal disorder 58 coinfected patients 58 SUSTENNA TM 58 squamous histology 58 chlorambucil 58 FDA APPROVES 58 Ag g tx 58 SCHIZOPHRENIA DISORDERS SUPPORT GROUP 58 Levels Linked 58 CCyR 58 ARIXTRA R 58 Lymphocytic 58 Jeg Coughlin Cobalt 58 receiving immunosuppressive therapy 58 Arch Intern Med 58 GALLON OF 58 abdominal distention 58 aldosterone antagonist 58 cardiac tamponade cerebral edema 58 fevers vomiting 58 subsyndromal 58 #q# deletion syndrome 58 headache chills 58 Depressive Symptoms 58 splenectomized patients 58 heartburn nausea 58 constipation somnolence nausea 58 left ventricular diastolic 58 mg Pycnogenol 58 Hypotension 58 mg clopidogrel 58 FOLFOX4 58 maximal tolerated 58 HMG CoA reductase inhibitors 58 BCG refractory carcinoma 58 heparin induced thrombocytopenia 58 Tasigna prolongs 58 PRADAXA #mg 58 FDA Approves Drug 58 vomiting muscle aches 58 non valvular atrial 58 Hb A1C 58 melphalan prednisone 58 BENICAR 58 Bronchiectasis 58 diabetes sciatica 58 pegylated alpha interferon 58 OAKLAND ATHLETICS Activated 58 repeat paracentesis 58 placebo PBO 58 IRLS 58 Sodium oxybate 58 #ug [001] 58 Symptom severity 58 beta carotene supplementation 58 vomiting diarrhea abdominal cramps 58 PENNSAID 58 WILL BE ISSUED 58 dose escalation phase 58 Chronic Angina 58 % asthenia malaise 58 nasal congestion sore throat 58 plus prednisone 58 Aptivus ® 58 PROCTOCORT R 58 evaluable subjects 58 containing abacavir 58 5mg/kg 58 P ≤ 58 Dermatologic toxicities 58 Survival Benefit 58 mg administered orally 58 novel VDA molecule 58 drotrecogin alfa activated 58 angiotensin II receptor blockers 58 certolizumab pegol 58 beta blockers ACE inhibitors 58 Eric Medlen Mustang 58 log# IU mL 58 limiting toxicity 58 Key secondary endpoints 58 somnolence headache 58 REGIONAL THEATER TONY AWARD 58 achieving PASI 58 conjunctival hyperemia 58 COZAAR 58 BY STEFANIE WHITE 58 #mg QD [002] 58 aspartate aminotransferase AST 58 Chris Rivas Buell 58 mean ± SEM 58 Morgellons sufferers describe 58 Pharmacokinetics PK 58 oral Hycamtin 58 mg RDEA# 58 gastroenteritis skin rashes 58 #mg dose [002] 58 #:#-#,# [002] 58 Vasomotor Symptoms 58 lispro 58 undetectable HBV DNA 58 DexaSite 58 involving oblivious texters 58 mesalamine granules 58 CPAP adherence 58 Combo Therapy 58 bone spurs bulging 58 sumatriptan naproxen sodium 58 refractory gout 58 maximally tolerated dose 58 STRATEGY FOR AN OPEN 58 folinic acid 58 ritonavir boosted atazanavir 58 hypertension congestive heart 58 Drug Prevents 58 dyslipidaemia 58 Elotuzumab 58 doripenem 58 XIENCE V PROMUS Stent 58 anagrelide 58 EQUETRO 58 AN EXISTING 58 Severely Obese 58 MLN EUROS 58 CR nPR 58 KETEK 58 active ankylosing spondylitis 58 #.#/#.# mm Hg [003] 58 serum transaminases 58 Ron Capps Charger 58 vincristine doxorubicin 58 Double Blind Randomized 58 EMBLEM ™ 58 runny nose headache 58 divalproex sodium 58 Natalizumab 58 arterial thromboembolic 58 pancreas esophagus 58 CIMZIA r certolizumab pegol 58 Uncontrolled hypertension 58 teriflunomide 58 alanine aminotransferase 58 confirmed CCyR 58 symptomatic pulmonary embolism 58 vaccine RiVax TM 58 Cancer Incidence Mortality 58 anemia neutropenia 58 hematological toxicities 58 urinary cortisol 58 Benazepril 58 atherothrombotic disease 58 Sanofi Pasteur Fluzone 58 cSSSIs 58 solid tumors ZYBRESTAT 58 sham injections 58 # viagra url 58 glycoprotein IIb IIIa inhibitor 58 Severe infusion 58 MoxDuo TM IR 58 NYHA Class II 58 octreotide LAR 58 elevated LDH 58 dizziness nausea headaches 58 Free Survival PFS 58 Fireworks resounded 58 peripheral arterial occlusive disease 58 ST Elevation Myocardial 58 neutropenic fever 58 % CI #.#-#.# [001] 58 takes ethosuximide 58 insulin detemir 58 Critically Ill Patients 58 angiotensin converting enzyme inhibitors 58 severe neutropenia 58 CLINICAL PHARMACOLOGY 58 Investigational Treatment 58 P = .# 58 Off Magazines 57 dopamine partial agonist 57 Belimumab 57 neurogenic orthostatic hypotension NOH 57 WARNINGS Myopathy Rhabdomyolysis 57 acarbose 57 permanently discontinue Vectibix 57 Parnate 57 systemic corticosteroid 57 concomitant medications 57 muscle aches fever 57 #:#-#,# CrossRef 57 acetaminophen codeine 57 anginal pain 57 Acute Coronary Syndromes ACS 57 Antidepressants Linked 57 NATIONAL ECONOMIC COUNCIL DIRECTOR 57 TRISCUIT crackers 57 Kokoraleis convicted 57 PANSS 57 ALIMTA cisplatin 57 Sustained virologic response 57 confidence interval CI 57 hypercholesterolaemia 57 locoregional recurrence 57 syncopal 57 Crohn Disease Activity 57 severe hepatic insufficiency 57 ulcerative colitis Crohn disease 57 NYFCC awarded 57 heart palpitations dizziness 57 Detrol Detrol LA 57 unfavorable cytogenetics 57 cerebrovascular events 57 INSPIRE Trial Phase III 57 Lucentis monotherapy 57 jaundice fatigue 57 Abrupt discontinuation 57 tolerability profiles 57 mean baseline A1C 57 ENABLE Phase 2 57 PRADAXA 57 aplastic anemia AA